Theratechnologies Presents Preclinical Data That Highlight Versatility And Flexibility Of SORT1+ Technology Platform

4/8/24 4:35:48 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $THTX alert in real time by email

In a poster session at the 2024 annual meeting of the American Association for Cancer Research (AACR) in San Diego, Calif., researchers reported that Theratechnologies' investigational camptothecin-peptide conjugates are well tolerated and associated with significant tumor regression in colorectal cancer (CRC) and triple-negative breast cancer (TNBC) xenograft models.

Get the next $THTX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$THTX

Date	Price Target	Rating	Analyst
11/17/2022	$9.00	Overweight	Cantor Fitzgerald
7/29/2021	$8.00 → $3.00	Buy → Hold	Canaccord Genuity

More analyst ratings

Theratechnologies Appoints Elina Tea to its Board of Directors
MONTREAL, April 05, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Elina Tea, Chief Financial Officer at GLS North America, to its Board of Directors and as a member of the Company's Audit Committee. Ms. Tea will be Investissement Québec's designee pursuant to its investor rights agreement with the Company. "Elina Tea's extensive experience in finance, corporate strategy, and investor relations makes her a valuable addition to our Board of Directors," said Dawn Svoronos, Chair of the Board o
4/5/24 11:00:00 AM ET
$THTX
Biotechnology: Pharmaceutical Preparations
Health Care
Theratechnologies Appoints Jordan Zwick to its Board of Directors
MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Jordan Zwick, Chief Business Officer at Mirador Therapeutics Inc., to its Board of Directors and as a member of the Company's Audit Committee. "We welcome Jordan Zwick to the Board as an important addition to our esteemed group of advisors," said Dawn Svoronos, Chair of the Board of Directors at Theratechnologies. "With his extensive experience in the U.S. biotech and pharmaceutical industry, coupled with expertise in global
3/21/24 8:00:00 PM ET
$THTX
Biotechnology: Pharmaceutical Preparations
Health Care
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau
MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Mr. Alain Trudeau has resigned from the Board of Directors of Theratechnologies and as a member of its Audit Committee, effective immediately. "I want to thank Alain for his contributions to Theratechnologies as a director since joining the Company in October 2020 and for completing the annual review for the 2023 fiscal year", said Dawn Svoronos, Chair of the Board at Theratechnologies. "Alain was the current Chair of the Audit Committee
2/29/24 4:34:00 PM ET
$THTX
Biotechnology: Pharmaceutical Preparations
Health Care

Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024
Q3 revenue of $22.6 million represents +8% growth year-over-yearPositive net income of $3.1 million or 6 cents per share, and Adjusted EBITDA1 of $7.2 million Fiscal 2024 guidance revised to between $83 and $85 million in revenue and Adjusted EBITDA guidance increased to a range of $17 to $19 million MONTREAL, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the third quarter of fiscal year 2024 ended August 31, 2024 (Q3 2024). All figures are in US dollars u
10/10/24 7:30:00 AM ET
$THTX
Biotechnology: Pharmaceutical Preparations
Health Care
Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update
MONTREAL, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its third quarter ended August 31, 2024, on Thursday, October 10 at 8:30 a.m. ET. The call will be hosted by Paul Lévesque, President and Chief Executive Officer. He will be joined by other members of the management team, including Philippe Dubuc, Senior Vice President and Chief Financial Officer, Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Offic
9/26/24 7:30:00 AM ET
$THTX
Biotechnology: Pharmaceutical Preparations
Health Care
Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024
Q2 revenue of $22 million represents +25% growth year-over-yearPositive net income of $1 million realized with Adjusted EBITDA1 of $5.5 million Fiscal 2024 revenue guidance confirmed between $87 and $90 million and an Adjusted EBITDA in the range of $13 to $15 million MONTREAL, July 10, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter of fiscal year 2024 ended May 31, 2024 (Q2 2024). All figures are in US dollars unless otherwise stated. Revenue fo
7/10/24 7:30:00 AM ET
$THTX
Biotechnology: Pharmaceutical Preparations
Health Care

Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV
MONTREAL, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on development and commercialization of innovative therapies, today announced data from two poster presentations, focusing on the association between excess visceral abdominal fat (EVAF) and cardiovascular disease (CVD) risk in people with HIV (PWH), and on the use of tesamorelin to reduce such risk. In a poster presentation at IDWeek 2024 in Los Angeles, Calif., investigators from the Visceral Adiposity Measurement and Observations Study (VAMOS) reported that EVAF is one of several risk factors that contribute to heightened
10/17/24 2:00:00 PM ET
$THTX
Biotechnology: Pharmaceutical Preparations
Health Care
Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance
MONTREAL, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on development and commercialization of innovative therapies, today disclosed the study design and baseline characteristics of participants in the Prospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States (PROMISE-US). The study seeks to fill a critical gap in long-term clinical outcomes for heavily treatment-experienced (HTE) people with HIV (PWH), while illuminating factors contributing to maintenance of virologic control. In a poster pre
10/17/24 7:30:00 AM ET
$THTX
Biotechnology: Pharmaceutical Preparations
Health Care
Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024
Q3 revenue of $22.6 million represents +8% growth year-over-yearPositive net income of $3.1 million or 6 cents per share, and Adjusted EBITDA1 of $7.2 million Fiscal 2024 guidance revised to between $83 and $85 million in revenue and Adjusted EBITDA guidance increased to a range of $17 to $19 million MONTREAL, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the third quarter of fiscal year 2024 ended August 31, 2024 (Q3 2024). All figures are in US dollars u
10/10/24 7:30:00 AM ET
$THTX
Biotechnology: Pharmaceutical Preparations
Health Care

Theratechnologies Presents Preclinical Data That Highlight Versatility And Flexibility Of SORT1+ Technology Platform

Chat with this insight

Recent Analyst Ratings for
$THTX

$THTX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Theratechnologies Inc.

SEC Form SC 13G/A filed by Theratechnologies Inc. (Amendment)

SEC Form SC 13D filed by Theratechnologies Inc.

$THTX
Leadership Updates

Live Leadership Updates

$THTX
Financials

Live finance-specific insights

Theratechnologies Appoints Elina Tea to its Board of Directors

Theratechnologies Appoints Jordan Zwick to its Board of Directors

Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau

Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024

Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update

Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024

$THTX
SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Theratechnologies Inc.

SEC Form 6-K filed by Theratechnologies Inc.

SEC Form 6-K filed by Theratechnologies Inc.

$THTX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Cantor Fitzgerald initiated coverage on Theratechnologies with a new price target

Theratechnologies downgraded by Canaccord Genuity with a new price target

Canaccord Genuity reiterated coverage on Theratechnologies with a new price target

$THTX
Market Insights

Live Market Insights

HIV Medicine Maker Theratechnologies 'Wraps Up Strong Second Quarter,' Stock Soars

Theratechnologies Reiterates FY24 Revenue Guidance Range Of $87M-$90M Vs. $87.88M Estimate

Theratechnologies Q2 Sales $22.02M Beat $21.71M Estimate, Company Ended Q2 With $36.03M In Cash

$THTX
Press Releases

Fastest customizable press release news feed in the world

Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV

Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance

Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024

Theratechnologies Presents Preclinical Data That Highlight Versatility And Flexibility Of SORT1+ Technology Platform

Chat with this insight

Recent Analyst Ratings for $THTX

$THTX Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Theratechnologies Inc.

SEC Form SC 13G/A filed by Theratechnologies Inc. (Amendment)

SEC Form SC 13D filed by Theratechnologies Inc.

$THTX Leadership Updates

Live Leadership Updates

$THTX Financials

Live finance-specific insights

Theratechnologies Appoints Elina Tea to its Board of Directors

Theratechnologies Appoints Jordan Zwick to its Board of Directors

Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau

Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024

Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update

Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024

$THTX SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Theratechnologies Inc.

SEC Form 6-K filed by Theratechnologies Inc.

SEC Form 6-K filed by Theratechnologies Inc.

$THTX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Cantor Fitzgerald initiated coverage on Theratechnologies with a new price target

Theratechnologies downgraded by Canaccord Genuity with a new price target

Canaccord Genuity reiterated coverage on Theratechnologies with a new price target

$THTX Market Insights

Live Market Insights

HIV Medicine Maker Theratechnologies 'Wraps Up Strong Second Quarter,' Stock Soars

Theratechnologies Reiterates FY24 Revenue Guidance Range Of $87M-$90M Vs. $87.88M Estimate

Theratechnologies Q2 Sales $22.02M Beat $21.71M Estimate, Company Ended Q2 With $36.03M In Cash

$THTX Press Releases

Fastest customizable press release news feed in the world

Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV

Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance

Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024

Recent Analyst Ratings for
$THTX

$THTX
Large Ownership Changes

$THTX
Leadership Updates

$THTX
Financials

$THTX
SEC Filings

$THTX
Analyst Ratings

$THTX
Market Insights

$THTX
Press Releases